SALT LAKE CITY, Aug. 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its management team will participate in the following upcoming investor conference: UBS Genomic Medicine Summit, August 13-14. President and Chief Executive Officer, Zhenya Lindgardt, will participate in a panel discussion: Future of Genetic Testing – B ...

The market expects UBS (UBS) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 14, 2024, might help the stock move higher if these key numbers are better than ...

UBS Group AG (UBS) sued Bank of America (BAC) yesterday for $200 million. The lawsuit, filed in a New York state court in Manhattan, alleged that the latter refused to cover the legal costs associated with risky mortgages issued before the 2008 financial crisis, per the Reuters report.The Swiss bank packaged mortgages from Countrywide Financial, which was acquired by Bank of America in 2008, into securities. The bank stated that Countrywide agreed to indemnify it against any claims that the mortgages were i ...

UBS analysts raised their price targets on Meta Platforms (NASDAQ:META) stock to $635 per share, reaffirming their “buy” rating on the back of stellar second-quarter earnings.Meta earned $13.46 billion, $5.16 per share, on revenue of $39 billion during the quarter ending in June. The company reported after the market closed yesterday. Earnings were up 73%, and revenue was up 22% from a year ago. All the numbers beat analyst estimates.META stock was trading early today at $502 per share, up about $30 or 6% o ...

Last week, UBS (NYSE:UBS) raised its year-end price target for the S&P 500 to 5,900, attributing the increase to a conducive environment for U.S. equities. The Swiss investment bank also introduced a mid-2025 forecast for the index, setting the target at 6,200, signaling confidence in the market’s future performance.The upgraded targets hinge on several pivotal factors, including robust earnings growth, the trend of disinflation, the prospect of interest rate reductions by the Federal Reserve, and a signifi ...

After Tesla (NASDAQ:TSLA) released its second-quarter results, which disappointed Wall Street, Swiss bank UBS reiterated its "sell" rating and $197 price target on Tesla stock. UBS' price target is about 10% below the stock's current level. TSLA stock is down about 11% this morning. Why UBS Is So Bearish on Tesla Stock According to UBS analyst Joseph Spak, Tesla's valuation is very high because investors believe that its initiatives in autonomy and artificial intelligence (AI) will bear great fruit in the f ...

Gold prices have surged in 2024 and judging by the latest analyst commentary, this trend is unlikely to stop anytime soon. UBS (NYSE:UBS) updated its gold price forecasts recently, raising its expectations for the precious metal’s future performance. The bank’s Chief Investment Officer (CIO) now anticipates gold to reach $2,500 per ounce by the end of September, up from the previous forecast of $2,400. Moreover, the year-end projection for 2024 has been increased to $2,600 per ounce from $2,500, with the sa ...

WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the UBS Virtual TPD Day on July 15, 2024, at 1:00 p.m. ET. A live webcast of the presentation will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A re ...

BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual UBS Targeted Protein Degradation Day on Monday, July 15, 2024, at 3:30 p.m. ET. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.mo ...

UBS Group AG (UBS) marks an important milestone in the integration of UBS and Credit Suisse by completing the merger of UBS Switzerland AG and Credit Suisse (Schweiz) AG. This merger aligns with UBS' growth strategy to strengthen its market presence in competitive regions.Following this merger, Credit Suisse (Schweiz) AG has been deregistered from the Commercial Register of the Canton of Zurich and no longer exists as a separate business. Consequently, UBS Switzerland AG now owns all the rights and obligati ...